Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Phio Pharmaceuticals Corp.PHIO · Entity 7889 | Director | September 24, 2026 | September 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Phio Pharmaceuticals Corp.
Report date September 24, 2026 · Filed September 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $.0001 par valueSEC Table I · non-derivative | Direct | 64,151 |
Reported balance
After 2026-09-24 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-24 · Purchase · Acquired 6,500 · Balance 64,151 F1: Includes shares of common stock underlying unvested restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes shares of common stock underlying unvested restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 24, 2026 Filed Sep 25, 2026 20:01 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | PurchaseCommon Stock, $.0001 par value | 6,500 | $1.01 | $6,582.55 |
DisclosureSEC source: 0001683168-26-007432 · ownership.xml · nonDerivative · entry 1 BRADFORD PATRICIA A · CIK 0001313325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,151 F1 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| September 15, 2026 Filed Sep 16, 2026 20:01 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | PurchaseCommon Stock, $.0001 par value | 12,000 | $1.03 | $12,360.00 |
DisclosureSEC source: 0001683168-26-007192 · ownership.xml · nonDerivative · entry 1 BRADFORD PATRICIA A · CIK 0001313325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,651 F1 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| February 05, 2026 Filed Feb 6, 2026 07:57 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon Stock, $.0001 par value | 18,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-26-000805 · ownership.xml · nonDerivative · entry 1 BRADFORD PATRICIA A · CIK 0001313325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,651 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest on the first annual anniversary of the grant. F2 · balance_after: Includes shares of common stock underlying unvested restricted stock units. F3 · balance_after: The number of reported securities has been adjusted to reflect prior reverse stock splits. Read SEC document |
| September 11, 2025 Filed Sep 15, 2025 08:28 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon Stock, $.0001 par value | 18,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-25-006955 · ownership.xml · nonDerivative · entry 1 BRADFORD PATRICIA A · CIK 0001313325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,151 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest on the first annual anniversary of the grant. F2 · balance_after: Includes shares of common stock underlying unvested restricted stock units. F3 · balance_after: The number of reported securities has been adjusted to reflect prior reverse stock splits. Read SEC document |
| September 11, 2024 Filed Sep 12, 2024 16:10 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon Stock, $0.0001 par value | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-24-006332 · ownership.xml · nonDerivative · entry 1 BRADFORD PATRICIA A · CIK 0001313325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,000 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest on the first annual anniversary of the grant. F2 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 19:10 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon stock, $0.0001 par value | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-011920 · doc4.xml · nonDerivative · entry 1 BRADFORD PATRICIA A · CIK 0001313325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,167 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. F2 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Effective as of 12:01 a.m. Eastern Time on January 26, 2023, the issuer effected a reverse split of its outstanding shares of common stock at a ratio of 1-for-12. Read SEC document |
| August 09, 2022 Filed Sep 26, 2022 19:00 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon stock, $0.0001 par value | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-051302 · doc4.xml · nonDerivative · entry 1 BRADFORD PATRICIA A · CIK 0001313325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.